Senores Pharmaceuticals Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹284(72.63%)
Premium (ELP)
Senores Pharmaceuticals Limited's completed its IPO journey with a successful listing on NSE, BSE on Dec 30, 2024. The public offering mobilized 1,48,87,723 Shares in total capital, comprising 1,27,87,723 Shares in fresh equity and ₹82.11 Cr in Offer for Sale shares from existing stakeholders.
The offering was conducted within the price band of ₹372 to ₹391, with minimum application lots of 38 shares. Investor participation during the Dec 20, 2024 to Dec 24, 2024 subscription window determined the final allocation pattern.
The basis of allotment was announced on Dec 26, 2024, finalizing share distribution to successful applicants. The listing represents a significant corporate development, providing the company with enhanced visibility and access to public capital markets.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Senores Pharmaceuticals Limited, incorporated on December 26, 2017, is an Ahmedabad-based pharmaceutical company focused on developing, manufacturing, and marketing high-quality branded generic medicines for both domestic and global markets. Its diversified product portfolio spans key therapeutic areas, including gastrointestinal, cardiovascular, respiratory, pain management, and anti-infective segments. Driven by strong R&D capabilities, the company emphasizes innovation, cost-effective product development, and strict regulatory compliance. Senores operates through a robust distribution network supported by subsidiaries such as Ratnatris Pharmaceuticals Private Limited and Havix Group, Inc. (Aavis Pharmaceuticals). It serves customers across major international markets, including the US, Europe, and other emerging regions.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Global Market Presence: Strong footprint across regulated and semi-regulated markets ensures diversified revenue and reduced geographical dependence.
- Robust R&D & Manufacturing: Advanced R&D capabilities enable development of complex generics while adhering to strict global regulatory standards for quality.
- Strategic Partnerships: Long-term relationships with major clients, suppliers, and distributors support steady growth and consistent revenue visibility.
- Regulatory Challenges: Delays or denials in product approvals may hinder new launches and limit growth in key markets.
- Raw Material Volatility: Dependence on external API and raw material suppliers exposes the company to price fluctuations and supply disruptions.
- Intense Competition: A highly competitive pharma landscape may pressure pricing and reduce profit margins.
- Swapnil Jatinbhai Shah
- Ashokkumar Vijaysinh Barot
Senores Pharmaceuticals Limited
Link Intime India Private Limited